|
|
 |
|
Viewing report
|
|
|
|
Beyond The Blockbuster Drug: Strategies For Nichebuster Drugs, Targeted Therapies and Personalized Medicine.
Business Insights, Feb 2005, Pages: 132
The blockbuster model now delivers just 5% return on investment and only one in six new drug prospects will deliver returns above their cost of capital, as a result competitive pressures and falling R&D productivity will instigate a new pharmaceutical model that replaces the unsustainable blockbuster model; personalized medicine and the 'nichebuster'.
This report, Beyond the Blockbuster Drug: Strategies for Nichebuster Drugs, Targeted Therapies and Personalized Medicine, examines targeted therapies and targeted drug delivery strategies as alternative investment options for pharmaceutical companies, in the face of declining returns and slow growth in the blockbuster market.
This report’s strategic insight is also supported by in-depth interviews with thought leaders from the pharmaceutical industry, providing you with their insight into how tomorrow’s pharmaceutical business model will develop. This report analyzes the niche pharmaceutical sectors with the greatest potential for profit and future growth. Harness the technological advances in personalized medicine and be part of the 'nichebuster' revolution set to drive market growth and produce the market leading drugs of tomorrow.
Key Findings of this Report:
- From 2005 to 2008, total blockbuster sales are forecast to demonstrate a CAGR of only 1.6% compared with the 9% forecast for the period 2002 to 2005.
- In order to grow by 10%, today's big pharmaceutical companies would need to launch two or three new blockbusters per year.
- Alliances and licensing will be increasingly critical to ‘BigPharma´s’ ability to access innovation in novel areas of science, new products in different therapeutic areas, and replacement compounds for late life-cycle drugs.
- Technologies such as genomics and proteomics have produced an explosion of new poorly validated targets that may actually increase the rate of compound attrition and the costs of R&D.
- Total pharmaceutical R&D outsourcing is expected to grow at a compound annual growth rate (CAGR) of 11-12% from its 2003 level of $7.9 billion, compared to anticipated growth in global R&D spending of only 9.6%.
Key questions answered in this Report:
- In 2006, which blockbuster drugs will be exposed to patent expiration to the value of US$17bn?
- What are the key factors slowing blockbuster market growth?
- What is the ‘nichebuster’ model and how will it fit into the future landscape of the industry?
- How is personalized medicine set to transform the future of the pharmaceutical industry?
- Which sectors are currently driving growth for targeted therapies?
- Which technologies will produce an explosion of poorly validated targets that may actually increase the rate of compound attrition and
the costs of R&D?
- What roles will alliances and partnering play in the development of the pharmaceutical sector beyond the blockbuster model?
Five Reasons to buy this Report:
- Understand how the new ‘nichebuster’ model will revolutionize the pharmaceutical sector and which new growth opportunities this model will promote.
- Harness the new era of personalized medicine guided by advances in biotechnology and genetic engineering, and take advantage of the larger opportunities multiple specialist disease areas offer.
- Analyze how leading players, such as Novartis and Roche, are using targeted therapies and R&D partnerships for faster growth and benchmark your portfolio growth strategy accordingly.
- Evaluate new drug delivery technologies, advances in proteomics and pharmacogenomics set to transform the pharmaceutical sector and identify which technological developments your company can exploit to gain a competitive edge in the market.
- Secure your frontline position in the future of the pharmaceutical industry by adapting your product portfolio to meet the healthcare needs of tomorrow.
Customers who bought this item also bought
Personalized Medicine - Scientific and Commercial Aspects
Personalized Medicine
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Innovative and Targeted Cancer Therapies: Key Technologies, New Applications and Leading Players
Cancer Personalized Medicine 2008
Drug Delivery Technology - Revolutionizing Cancer Therapies
Personalized Medicine: The Impact of Pharmacogenomics on Pharmaceutical R&D and Sales
Fulfilling the Promise of Personalized Medicine Through Next-Generation Sequencing
Expanding Applications of Personalized Medicine: Use of Biomarkers in Prognostic, Predictive and Pharmacogenetic Tests in a Targeted Approach
Targeted Cancer Therapies: Innovative Drugs And Their Impact On The Future Of Oncology
Drug Delivery in Cancer - Technologies, Markets and Companies
Dealmaking and Business Strategies in the Age of Personalized Medicine
|
|
|
|
